drugset / Trial / NCT01609478

Efficacy, Safety and Pharmacokinetics of Indacaterol Acetate in Patients With Persistent Asthma

NCT01609478

Phase 2 Completed 335 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

To provide the efficacy, safety and pharmacokinetics of indacaterol acetate in patients with persistent asthma to support dose selection of indacaterol in fixed dose combination QMF149.

Timeline

Start
2012-08
Primary completion
2013-07
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Indacaterol Other / unclassified 75 ug Inhaled
Subject Indacaterol Other / unclassified 150 ug Inhaled
Background Mometasone furoate Other / unclassified 200 ug Inhaled

Indications